Stay updated on Pembrolizumab & Lenalidomide in Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Lenalidomide in Lymphoma Clinical Trial page.

Latest updates to the Pembrolizumab & Lenalidomide in Lymphoma Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedPage revision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check18 days agoNo Change Detected
- Check32 days agoChange DetectedRevision label on the page updated from v3.4.1 to v3.4.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check39 days agoChange DetectedThe update is a minor metadata revision (Revision: v3.4.1 added; Revision: v3.4.0 removed) with no changes to study data or page content; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check61 days agoChange DetectedPage revision updated from v3.3.3 to v3.3.4.SummaryDifference0.1%

- Check83 days agoChange DetectedAdded a dedicated Locations section listing study sites in Georgia, Massachusetts, and New York (Atlanta/Emory, Boston/MGH, New York/NYU Perlmutter) and updated the record to revision v3.3.3. The HHS Vulnerability Disclosure footer link was removed.SummaryDifference0.4%

- Check112 days agoChange DetectedRevision: v3.3.2 was added in the Study Documents section, replacing v3.2.0, with no substantive changes to the study details.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab & Lenalidomide in Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Lenalidomide in Lymphoma Clinical Trial page.